Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
ASHA
|
October 31, 1998
Schools SID? A response
L Aungst
Journal of Neurophysiology
|
October 21, 2011
Serotonin modulates the population activity profile of olfactory bulb external tufted cells
Shaolin Liu, Jason L Aungst, Adam C Puche, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
April 24, 2014
Repeated mild traumatic brain injury causes chronic neuroinflammation, changes in hippocampal synaptic plasticity, and associated cognitive deficits
Stephanie L Aungst, Shruti V Kabadi, Scott M Thompson, et al.
Nature
|
December 12, 2003
Centre-surround inhibition among olfactory bulb glomeruli
J L Aungst, P M Heyward, A C Puche, et al.
Forensic Science International
|
November 26, 2021
Is it COVID-19? The value of medicolegal autopsies during the first year of the COVID-19 pandemic
Rachel L Geller, Jenna L Aungst, Anna Newton-Levinson, et al.
The Oncologist
|
July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Gautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2013
EADB: an estrogenic activity database for assessing potential endocrine activity
Jie Shen, Lei Xu, Hong Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Michael I Barbato, Diana Bradford, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
Sonia Singh, Diana Bradford, Somak Chatterjee, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
ASHA
|
October 31, 1998
Schools SID? A response
L Aungst
Journal of Neurophysiology
|
October 21, 2011
Serotonin modulates the population activity profile of olfactory bulb external tufted cells
Shaolin Liu, Jason L Aungst, Adam C Puche, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
April 24, 2014
Repeated mild traumatic brain injury causes chronic neuroinflammation, changes in hippocampal synaptic plasticity, and associated cognitive deficits
Stephanie L Aungst, Shruti V Kabadi, Scott M Thompson, et al.
Nature
|
December 12, 2003
Centre-surround inhibition among olfactory bulb glomeruli
J L Aungst, P M Heyward, A C Puche, et al.
Forensic Science International
|
November 26, 2021
Is it COVID-19? The value of medicolegal autopsies during the first year of the COVID-19 pandemic
Rachel L Geller, Jenna L Aungst, Anna Newton-Levinson, et al.
The Oncologist
|
July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Gautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 31, 2013
EADB: an estrogenic activity database for assessing potential endocrine activity
Jie Shen, Lei Xu, Hong Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Michael I Barbato, Diana Bradford, Yi Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
Sonia Singh, Diana Bradford, Somak Chatterjee, et al.
Page
of 1